Shift Pharmaceuticals is a startup drug development company with a platform technology for utilizing a Morpholino based Antisense Oligos (MAO) for treatment of neurodegenerative diseases. The core platform has been validated (with peer-reviewed publications) by our academic partners at The University of Missouri targeting Spinal Muscular Atrophy (SMA), which is our initial clinical focus. Intellectual property has been filed by the University and approved by the USPTO.
University of Missouri - Columbia
Steve O'Connor, CEO
Chris Lorson, CSO
Paul Marcos, Director of R&D
Patents have been filed and approved by University of Missouri - Columbia and exclusively licensed to Shift.